VERITAS - Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy

Written By 3B Digital

Chief Investigator: Dr Dominique Valteau-Couanet

Sponsor: Institut Gustave Roussy, Paris

Funder/Charity: Institut National du Cancer

International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy.

This study aims to improve the outcome for patients with high risk neuroblastoma which is refractory to induction chemotherapy

The trial is a prospective, open-label, randomised, multi-centre phase 2 trial. It aims to evaluate the efficacy of two intensified consolidation strategies:

  • high dose 131I-mIBG therapy with topotecan, followed by high dose Busulfan-Melphalan (Bu-Mel)

  • High dose thiotepa followed by high dose Bu-Mel

Each phase of the intensified treatment is supported by autologous stem cell rescue (ASCR).

The trial opened in October 2018 and is now closed. It has recruited 34 patients. A total of 78 sites participated, including France, Spain, The Netherlands, Italy, the UK, Austria, Germany and Israel.

No results are available from the study yet

Further details about the trial can be found at clinicaltrials.gov database: https://clinicaltrials.gov/ct2/show/NCT03165292

3B Digital https://www.3bweb.com
Previous

SIOPEN Low and Intermediate Risk Neuroblastoma European Study (LINES)
Next

A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma (The BEACON trial)